Aptamer for NGF and use thereof
AssigneesFujimoto Pharmaceutical Corporation, Ribomic Inc.
InventorsYoshikazu Nakamura, Ling Jin, Hisanao Hiramatsu
Life of this patent
Estimating the term…
Abstract
Provided is a higher quality aptamer having a binding activity to NGF. An aptamer binding to NGF, which satisfies the following (1) and (2): (1) containing the sequence represented by UGAAARAAACC (SEQ ID NO: 64) or CGAAMRAAACU (SEQ ID NO: 65), and (2) having a base length of not more than 73.
Claims16
An aptamer of 73 nucleotides or fewer, comprising any one of the nucleotide sequences (a), (b) or (c) below:
- (a) a nucleotide sequence shown by SEQ ID NO:
- 26, wherein uracil may be thymine;
- (b) a nucleotide sequence shown by SEQ ID NO:
- 26, wherein uracil may be thymine,
- wherein 1 to 4 nucleotides other than in the sequence UGAAAGAAACC (SEQ ID NO:
- 67) are substituted, deleted, inserted or added;
- (c) a nucleotide sequence having an identity of 90% or more to the nucleotide sequence of SEQ ID NO:
- 26, wherein uracil may be thymine, that comprises the sequence UGAAAGAAACC (SEQ ID NO:
- 67);
- wherein the aptamer binds to Nerve Growth Factor (NGF) and inhibits the following (i) and/or (ii):
- (i) binding of NGF to an NGF receptor;
- (ii) neurite outgrowth activity or cell proliferation activity of NGF.
A nucleic acid comprising the nucleotide sequence shown by SEQ ID NO:
- 26 and having a base length of not more than 73.
A nucleic acid consisting of the nucleotide sequence shown by SEQ ID NO:
- 26.
A pharmaceutical composition comprising:
- an aptamer of 73 nucleotides or fewer, comprising any one of the nucleotide sequences (a), (b) or (c) below:
- (a) a nucleotide sequence shown by SEQ ID NO:
- 26, wherein uracil may be thymine;
- (b) a nucleotide sequence shown by SEQ ID NO:
- 26, wherein uracil may be thymine,
- wherein 1 to 4 nucleotides other than in the sequence UGAAAGAAACC (SEQ ID NO:
- 67) are substituted, deleted, inserted or added;
- (c) a nucleotide sequence having an identity of 90% or more to the nucleotide sequence of SEQ ID NO:
- 26, wherein uracil may be thymine, that comprises the sequence UGAAAGAAACC (SEQ ID NO:
- 67);
- wherein the aptamer binds to Nerve Growth Factor (NGF) and inhibits binding of NGF to an NGF receptor;
- or
- (d) a complex comprising (a) or (b) or (c) above, and a labeling substance, enzyme, drug delivery vehicle or drug, which is combined with the aptamer.
An anti-pain medicament comprising:
- an aptamer of 73 nucleotides or fewer, comprising any one of the nucleotide sequences (a), (b) or (c) below:
- (a) a nucleotide sequence shown by SEQ ID NO:
- 26, wherein uracil may be thymine;
- (b) a nucleotide sequence shown by SEQ ID NO:
- 26, wherein uracil may be thymine,
- wherein 1 to 4 nucleotides other than in the sequence UGAAAGAAACC (SEQ ID NO:
- 67) are substituted, deleted, inserted or added;
- (c) a nucleotide sequence having an identity of 90% or more to the nucleotide sequence of SEQ ID NO:
- 26, wherein uracil may be thymine, that comprises the sequence UGAAAGAAACC (SEQ ID NO:
- 67);
- wherein the aptamer binds to Nerve Growth Factor (NGF) and inhibits binding of NGF to an NGF receptor;
- or
- (d) a complex comprising (a) or (b) or (c) above, and an enzyme, drug delivery vehicle or drug, which is combined with the aptamer.
Dependencies are inferred from the claim text.